Jobtacular.com

About Jobtacular.com

Welcome to TelehealthFX Talk, the evidence-based podcast that cuts through the hype of the rapidly evolving world of clinical weight loss and metabolic medicine.Whether you are navigating the transition to GLP-1 medications like semaglutide and tirzepatide, exploring complementary therapies like sermorelin and NAD+, or looking for natural metabolic support with berberine, we provide the honest, research-backed science you need to make informed decisions. Each week, we break down complex topics—from managing side effects and breaking through weight loss plateaus to preserving lean muscle mass and understanding the latest FDA updates.It is time to silence the food noise and optimize your metabolic health. Hit subscribe to stay up-to-date with the latest breakthroughs in clinical wellness, and visit us at telehealthfx.com to learn more about our comprehensive clinical programs.

Publisher

Telehealth FX

Category

health & fitness

Language

en

Explicit

No

First episode

18 Jun 2025

Latest episode

20 Sept 2026

Latest episodes

51 episodes in the feed.

1. 

   20 Sept 2026

   The Top Tirzepatide Clinics: Why You Must Follow the "Both Protocol"

   Take the free GLP-1 qualification quiz at https://telehealthfx.com — TelehealthFX offers the 'Both Protocol': seamless access to both compounded semaglutide and compounded tirzepatide under one roof so you never get trapped at a metabolic weight loss plateau. If you are researching modern medical weight loss options like Zepbound and Mounjaro, you know that tirzepatide is widely regarded as the most potent peptide therapy available today. Because it activates both GLP-1 and GIP receptors simultaneously, clinical trials consistently demonstrate superior total fat loss compared to single-agonist medications. However, when evaluating online weight loss clinics, patients run into a frustrating bottleneck: many popular platforms don't offer tirzepatide at all—they exclusively sell semaglutide. In Episode 40 of TelehealthFX Talk, our clinical hosts explain why signing up with a single-medication clinic artificially caps your long-term success. We break down the biological inevitability of the six-month weight loss plateau, the friction of switching providers mid-treatment, and why following the 'Both Protocol' from day one is the smartest way to safeguard your metabolic transformation. WHAT WE COVER IN THIS EPISODE: 1. THE SEMAGLUTIDE-ONLY CORPORATE TRAP Why do so many telehealth platforms avoid compounded tirzepatide? It comes down to raw API costs and dose-tiering logistics. Sourcing high-purity tirzepatide is significantly more expensive for compounding pharmacies. To protect margins and avoid tiered pricing, mass-market platforms run a semaglutide-only factory. If you sign up with one of these clinics, your long-term options are restricted from day one. 2. THE INEVITABLE SIX-MONTH METABOLIC PLATEAU Semaglutide is fantastic for initial progress, helping patients drop their first 20 to 30 pounds. But eventually, mammalian biology adapts. In a prolonged caloric deficit, your body downregulates metabolic rate. Once you reach the maximum dose of semaglutide and hit a biological plateau, a semaglutide-only clinic has exhausted its clinical toolbox. They keep billing you monthly, but the scale refuses to move. 3. THE FRICTION OF SWITCHING CLINICS MID-TREATMENT To break through a stubborn plateau, upgrading to a dual-agonist (tirzepatide) to recruit the GIP receptor is often clinically necessary. But if your provider doesn't dispense it, you are forced to cancel your subscription, hunt down a new clinic, pay a second intake fee, repeat intake with new doctors, and wait weeks for a new pharmacy. This administrative friction causes countless patients to abandon treatment altogether. 4. THE 'BOTH PROTOCOL' SOLUTION The 'Both Protocol' is simple: only partner with a telehealth provider that maintains established US compounding pharmacy supply chains for BOTH semaglutide and tirzepatide before your first injection. This empowers you to start on cost-effective semaglutide for initial weight loss. Then, if your progress stalls, your provider seamlessly upgrades your protocol to tirzepatide within the exact same patient portal—no extra fees, no new paperwork, and no disruption to your treatment. 5. METABOLIC ADJUNCTS: PROTECTING LEAN MUSCLE & ENERGY Because dual-agonists trigger rapid fat loss, patients face elevated risks of muscle wasting (sarcopenia) and fatigue. TelehealthFX pairs incretin therapies with metabolic adjuncts: subcutaneous NAD+ injections to restore mitochondrial energy, and Sermorelin to naturally stimulate growth hormone and preserve lean muscle mass. THE TELEHEALTHFX ADVANTAGE: - Complete 'Both Protocol' (Semaglutide & Tirzepatide Available) - Seamless Protocol Pivoting Without Switching Clinics - 100% FDA-Registered US 503A Compounding Pharmacies - Dedicated 24-Hour Licensed Medical Provider Review - Fast 2-Day UPS Cold-Chain Shipping - Access to Muscle-Preserving Adjuncts (NAD+ & Sermorelin) OFFICIAL LINKS: Qualification Quiz: https://go.telehealthfx.com/start Berberine Options: https://go.telehealthfx.com/berberine Official Website: https://telehealthfx.com TIMESTAMPS: 0:00 - Introduction: The Problem with Single-Medication Clinics 1:20 - The Semaglutide-Only Trap: Profit Margins vs Care 2:40 - The Biology of the 6-Month Weight Loss Plateau 3:50 - The Friction of Switching Clinics Mid-Treatment 4:55 - The 'Both Protocol': Strategic Planning from Day One 6:10 - Metabolic Adjuncts: NAD+ & Sermorelin 7:15 - How to Access Both Semaglutide and Tirzepatide MEDICAL DISCLAIMER: Educational only. Consult a physician before starting prescription GLP-1 medications. Results vary. #TopTirzepatideClinics #BothProtocol #ZepboundAlternative #MounjaroAlternative #GLP1WeightLoss #SemaglutidePlateau #TelehealthFX #CompoundedTirzepatide #WeightLossTelehealth #AffordableGLP1 #MedicalWeightLoss #DualAgonist #PeptideTherapy #NADTherapy #Sermorelin #NoHiddenFees #HealthyLivingOnline

2. 

   16 Sept 2026

   Mounjaro vs. Ozempic: Which Name-Brand GLP-1 Actually Works Better? (2026 Data)

   Take the free GLP-1 qualification quiz at https://go.telehealthfx.com/start — see if you're eligible for semaglutide or tirzepatide, the same active ingredients behind Ozempic and Mounjaro, delivered to your door with no hidden membership fees. Learn more at https://telehealthfx.com or explore berberine options at https://go.telehealthfx.com/berberine. Mounjaro vs. Ozempic — everyone's asking which GLP-1 actually wins. In this episode of TelehealthFX Talk, we break down what the real clinical data says about tirzepatide (Mounjaro) versus semaglutide (Ozempic), including the SURPASS-2 head-to-head trial, the mechanism difference that explains the weight loss gap, and why the "which one's better" question isn't as simple as the headlines make it sound. What we cover in this episode: - The core mechanism difference: Ozempic activates one receptor (GLP-1), Mounjaro activates two (GLP-1 and GIP) - SURPASS-2 trial results — the largest head-to-head comparison between tirzepatide and semaglutide - Why weight loss percentage comparisons you see online often mix different trial populations - An honest look at side effects — nausea, vomiting, diarrhea, and constipation rates for both drugs - Serious risk warnings shared by both medications: pancreatitis, gallbladder events, and thyroid C-cell signals - Why Ozempic carries FDA approval for cardiovascular and kidney risk reduction that Mounjaro doesn't yet have - Clearing up the brand confusion: Ozempic/Wegovy are semaglutide, Mounjaro/Zepbound are tirzepatide - Why a licensed provider — not a comparison chart — should guide your choice between the two Whether you're just starting to research GLP-1 medications or trying to decide between semaglutide and tirzepatide, this episode gives you the clinical context behind the two biggest names in weight loss medication today. TelehealthFX connects you with the same active ingredients found in Mounjaro and Ozempic — tirzepatide and semaglutide — through licensed U.S. compounding pharmacies, with 24-hour provider review, 2-day UPS shipping, and 1-on-1 onboarding support. No hidden membership fees. No confusing pricing tiers. Just transparent access to clinical weight loss support, licensed in all 50 states. Program highlights: - Semaglutide and tirzepatide available through one platform - 24-hour provider review after you complete the qualification quiz - 2-day UPS shipping straight to your door - Licensed US compounding pharmacies - 1-on-1 onboarding support to help you get started with confidence - Transparent pricing with no hidden membership fees - Licensed in all 50 states - NAD+ and sermorelin also available for those exploring broader wellness support Common questions this episode answers: - Is Mounjaro really more effective than Ozempic, or is that just marketing? - Why do Mounjaro and Ozempic have different side effect reputations if the data says they're similar? - Can you switch from Ozempic to Mounjaro, or vice versa? - What's the actual difference between Ozempic and Wegovy, or Mounjaro and Zepbound? - Does insurance coverage tell you anything about which drug is clinically better? (Short answer: no.) - Why does a GLP-1 medication that works well for one person not work the same way for someone else? Choosing between semaglutide and tirzepatide isn't about picking the "winning" drug off a chart — it's about matching the medication to your own health history, tolerance, and goals, with a licensed provider guiding the process. That's the gap TelehealthFX is built to close: real clinical support, without the brand-name price tag or the guesswork. Take the quiz at https://go.telehealthfx.com/start to see which option might be the right fit for your goals, or visit https://telehealthfx.com to learn more about how the program works. If you're curious about natural alternatives alongside or instead of GLP-1 medication, check out https://go.telehealthfx.com/berberine. This podcast is for educational purposes only and does not constitute medical advice. Individual results vary. Always consult a licensed healthcare provider before starting, stopping, or switching any weight loss medication. Mounjaro and Ozempic are registered trademarks of their respective manufacturers; TelehealthFX is not affiliated with Eli Lilly or Novo Nordisk. #GLP1 #WeightLoss #Semaglutide #Tirzepatide #OzempicAlternative #TelehealthWeightLoss #TelehealthFX #CompoundedSemaglutide #WeightLossMedication #Mounjaro #Ozempic #Zepbound #Wegovy #ClinicalWeightLoss #WeightManagement #FatBurning #DietPill #InsulinResistance #GLP1ForWeightLoss #WeightLossDelivered #RapidFatLoss #WeightLossForWomen #WeightLossForSeniors #TirzepatideVsSemaglutide #MounjaroVsOzempic #GLP1Comparison #WeightLossJourney #TelehealthMedicine #NADTherapy #Sermorelin

3. 

   16 Sept 2026

   Wegovy vs. Zepbound: The Name-Brand GLP-1 Showdown — Which One Actually Wins in 2026?

   Take the free GLP-1 qualification quiz at https://go.telehealthfx.com/start — see if you're eligible for semaglutide or tirzepatide, delivered to your door with no hidden membership fees. Learn more at https://telehealthfx.com or explore berberine options at https://go.telehealthfx.com/berberine. Wegovy and Zepbound are the two biggest names in GLP-1 weight loss medication, and for the first time, we actually have head-to-head trial data comparing them directly. In this episode of TelehealthFX Talk, we break down the SURMOUNT-5 head-to-head trial results, the real difference between semaglutide (Wegovy) and tirzepatide (Zepbound), and why the drug with more average weight loss isn't automatically the right choice for every person. What we cover in this episode: - The SURMOUNT-5 head-to-head trial results and what the percentages mean in real pounds - Why Zepbound's dual GIP/GLP-1 mechanism tends to outperform Wegovy's single-receptor approach - The honest side-effect comparison — nausea, vomiting, diarrhea, and constipation rates - Why Wegovy's cardiovascular outcomes data (the SELECT trial) matters for heart disease patients - The new oral Wegovy pill and Wegovy HD, and what they mean for needle-averse patients - Shared contraindications to know before starting either medication - Why a licensed provider — not a search result — should make the final call TelehealthFX offers a straightforward path to both semaglutide and tirzepatide, along with NAD+ and sermorelin, all backed by real clinical support. No hidden membership fees. No confusing contracts. Just transparent pricing, a 24-hour provider review, licensed U.S. compounding pharmacies, 2-day UPS shipping once you're approved, and 1-on-1 onboarding support to help you get started the right way. TelehealthFX is licensed in all 50 states, so no matter where you're watching from, you can find out if you qualify. If you're comparing Ozempic alternatives, researching compounded semaglutide or compounded tirzepatide, or just trying to figure out which GLP-1 medication delivered to your door actually makes sense for your goals, this episode walks through the clinical evidence in plain language, no medical degree required. We also touch on where berberine and other natural options fit for people exploring alternatives to prescription GLP-1 therapy, and why real clinical oversight looks different from a subscription box with a doctor's signature stapled to it. This content is for educational purposes only and is not a substitute for professional medical advice. Individual results vary. Always consult with a licensed healthcare provider before starting, stopping, or changing any medication or treatment plan discussed in this episode. Ready to find out which option might be right for you? Take the free qualification quiz now at https://go.telehealthfx.com/start. Curious about berberine as a natural complement or alternative? Check out https://go.telehealthfx.com/berberine. Or explore the full TelehealthFX program, including semaglutide, tirzepatide, NAD+ therapy, and sermorelin, at https://telehealthfx.com. Subscribe to TelehealthFX Talk for new episodes covering GLP-1 medications, telehealth weight loss programs, compounded medication safety, and the science behind sustainable weight management. New episodes drop regularly, and we're always digging into the questions our listeners are actually searching for, so drop your topic requests in the comments below. Quick FAQ from this episode: Is Zepbound stronger than Wegovy? In head-to-head trial data, tirzepatide (Zepbound) produced a larger average percentage of body weight loss than semaglutide (Wegovy) over 72 weeks. "Stronger" isn't the same as "better for you" though — side-effect tolerance and existing health conditions matter just as much as the topline number. Does Wegovy or Zepbound have worse side effects? Trial data shows Wegovy associated with somewhat higher rates of nausea, vomiting, and diarrhea, while Zepbound's GI side effects tend to be more concentrated right after a dose increase. Is there a pill version of either medication? Yes — an oral version of Wegovy launched in January, giving needle-averse patients a daily tablet option alongside the weekly injection. Which one is better for heart health? Wegovy has completed cardiovascular outcomes data showing a meaningful reduction in major cardiovascular events for people with existing heart disease. Zepbound's equivalent trial is still ongoing. Can I get either through telehealth? Many platforms offer semaglutide or tirzepatide, including compounded formulations through licensed U.S. pharmacies, after a clinical intake and provider review. TelehealthFX offers both with transparent pricing and no hidden membership fees. #GLP1 #WeightLoss #Semaglutide #Tirzepatide #OzempicAlternative #TelehealthWeightLoss #TelehealthFX #CompoundedSemaglutide #WeightLossMedication #Berberine #Dihydroberberine #BerberineWeightLoss #NADTherapy #Sermorelin #Liraglutide #Wegovy #Zepbound #ClinicalWeightLoss #WeightManagement #FatBurning #DietPill #PCOSWeightLoss #InsulinResistance #GLP1ForWeightLoss #WeightLossDelivered #RapidFatLoss #WeightLossForWomen #WeightLossForSeniors #Mounjaro #Ozempic

Podcast Authority Score: 14 / 100

A composite of feed quality, social presence, YouTube performance and engagement. Read the methodology.

Quality

29

Social presence

0

YouTube

0

Engagement

0

Contact Jobtacular.com

Guest appearances

Does not typically book guests

Based on episode analysis; this does not confirm that the show is currently accepting guests.